Market closedNon-fractional
Kyverna Therapeutics/KYTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
KYTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Emeryville, United States
Employees
100
Website
kyvernatx.com
KYTX Metrics
BasicAdvanced
$384M
Market cap
-
P/E ratio
-$11.90
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$384M
Financial strength
Current ratio
17.173
Quick ratio
16.913
Long term debt to equity
1.975
Total debt to equity
3.005
Interest coverage (TTM)
-423.63%
Management effectiveness
Valuation
Price to book
1.07
Price to tangible book (TTM)
1.07
Price to free cash flow (TTM)
-0.84
Growth
What the Analysts think about KYTX
Analyst Ratings
Majority rating from 4 analysts.
KYTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$27M
29.13%
Profit margin
0.00%
NaN%
KYTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$26.86
-$1.12
-
Expected
-$3.23
-$0.84
-$0.74
Surprise
732.44%
33.33%
-
KYTX News
AllArticlesVideos
The Schall Law Firm Welcomes Stakeholders Of Kyverna Therapeutics Inc To Join The Kytx Securities Fraud Probe
Accesswire·4 hours ago
The Schall Law Firm Welcomes Stakeholders Of Kyverna Therapeutics Inc To Join The KYTX Securities Fraud Probe
Accesswire·1 day ago
The Schall Law Firm Welcomes Stakeholders Of Kyverna Therapeutics Inc To Join The KYTX Securities Fraud Probe
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kyverna Therapeutics stock?
Kyverna Therapeutics (KYTX) has a market cap of $384M as of July 26, 2024.
What is the P/E ratio for Kyverna Therapeutics stock?
The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of July 26, 2024.
Does Kyverna Therapeutics stock pay dividends?
No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Kyverna Therapeutics dividend payment date?
Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.
Buy or sell Kyverna Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.